| [March 31, 2016] |
 |
Selexis SA Announces Spring 2016 Conference Schedule
Selexis SA, a pioneering life sciences company and a global leader in
mammalian (suspension-adapted CHO-K1) cell line generation, announced
today its planned participation at several conferences this Spring, as
follows:
-
BIO-Europe Spring® 2016
4 - 6 April 2016,
Berzelii Park, Stockholm, Sweden
Selexis Chief Executive
Officer and Chairman Igor Fisch, PhD, will participate in a panel
discussion entitled "The Alliance Manager: Bridging the Culture Gap,"
on 4 April at 2:45 p.m. CET. Selexis will also be participating in the
partnering program
For more information visit: http://www.ebdgroup.com/bes
-
Cell Line Development & Engineering: Practical Strategies to
Improve Cell Line Quality, Enhance Productivity and Increase
Throughput without Compromising Timelines
11 - 13
April 2016, Reed Messe Wien Congress Center, Vienna, Austria
Selexis
Scientific Founder, Board Member and Scientific Advisor Nicolas
Mermod, PhD, University of Lausanne, will present on 12 April at 4:05
p.m. CET during the Selection Strategies session on "Implementing Next
Generation Sequencing in Routine Cell Line Development." Selexis is
also a sponsor and exhibitor.
For more information visit: http://www.informa-ls.com/event/CellLine16
-
12th Annual PEGS Boston: The Essential
Protein Engineering Summit
25 - 29 April 2016,
Seaport World Trade Center, Boston, Massachusetts, USA
Selexis
Chief Scientific Officer Pierre-Alain Girod, PhD, will present on 27
April at 12:25 p.m. EST during the Optimizing Antibody Selection and
Screening session on "Analysis of the Genomics and Transcriptomics of
CHO-K1 to Accelerate and De-risk Biologics Development." Selexis is
also a sponsor and exhibitor.
For more information visit: http://www.pegsummit.com/
-
2016 BIO International Convention
6 - 9 June
2016, Moscone Center, San Francisco, California, USA
Selexis
will be participating in the partnering program and is also an
exhibitor.
For more Information visit: http://convention.bio.org/2016/
About Selexis SA
Selexis SA is a pioneering life sciences company and a global leader in
mammalian (suspension-adapted CHO-K1) cell line generation, providing
unparalleled proprietary technology and the highly specialized expertise
that is necessary to translate scientific innovation into life-saving
medicines for patients. Selexis's SUREtechnology Platform™
facilitates the rapid, stable, and cost-effective production of
virtually any recombinant protein and provides seamless integration of
the bioproduction continuum, spanning discovery to commercialization.
With nearly 90 clients worldwide and more than 65 drug products in
clinical and commercial manufacturing utilizing its cell lines, Selexis
has a history of empowering scientists and biopharmaceutical companies
around the world to realize the full potential of their research.
FOR MORE INFORMATION
View source version on businesswire.com: http://www.businesswire.com/news/home/20160331005077/en/
[ Back To TMCnet.com's Homepage ]
|
